Parkinson’s Disease Increased Over 30-Year Period, Study Shows
The incidence of Parkinson’s disease (PD) and parkinsonism increased significantly in the 30 years from 1976 to 2005, according…
Articles by Ana de Barros, PhD
Michael J. Fox Foundation Offering $2M to Develop PET Tracer to Visualize Alpha-Synuclein
The Michael J. Fox Foundation (MJFF)Â announced it has set aside a $2 million prize for the development of a…
Parkinson’s Disease Foundation Awards $4M in Research Funding for Early-Career Scientists
The Parkinson’s Disease Foundation (PDF) has announced research investments of $4 million for early career scientists addressing Parkinson’s…
Early Identification of Parkinson’s Leads to New Approaches to Tests, Biomarkers, Biopsies
One of the main topics discussed at the 2nd Congress of the European Academy of Neurology (EAN) in Copenhagen, Denmark, focused on…
Phase 2 Data of Dipraglurant for Parkinson’s-associated, Levodopa-induced Dyskinesia Announced by Addex
Addex Therapeutics recently published the results of the company’s Phase 2 trial of its drug candidate dipraglurant in patients with…
Parkinson’s Research Gets Boost with Cellular Dynamics, Michael J. Fox Foundation Collaboration
Cellular Dynamics International (CDI) has recently joined a Michael J. Fox Foundation for Parkinson’s Research (MJFF) effort by agreeing to…
PhotoPharmics Investigating Efficacy of Phototherapy for Parkinson’s Disease
PhotoPharmics, Inc. is currently conducting a pivotal study to demonstrate the safety and efficacy of specialized phototherapy for…
Michael J. Fox Foundation Calls Cyclists to Pedal for Parkinson’s Research in Tour de Fox 2016 Series
The Michael J. Fox Foundation (MJFF) has announced the start of the Tour de Fox 2016 Series. The…
Senior Helpers Now Offering In-Home Training Program for Parkinson’s Disease Caregivers
Senior Helpers has launched its Parkinson’s Care Program, developed together with specialists from the National Parkinson Foundation’s Center of Excellence, to provide…
FDA Approves a First Drug, Nuplazid (Pimavanserin), to Treat Parkinson’s Psychosis
The U.S. Food and Drug Administration (FDA) has approved for the first time a drug to treat the hallucinations and delusions associated with…